Story perspectives

New Obesity Guidelines: Semaglutide, Tirzepatide Offer Hope Amid Costs

10/3/2025

Summary

Story summary

The European Association for the Study of Obesity (EASO) recommends semaglutide and tirzepatide as primary pharmacotherapies for obesity and related complications.
Tirzepatide can yield 20% weight loss over 72 weeks.
Framework prioritizes patient-centered care, considering health conditions and socioeconomic factors.
High costs restrict accessibility, notably in Spain.
Guidelines should update as evidence emerges; experts urge combining medication with lifestyle changes.

1 of 1

Story summary

The European Association for the Study of Obesity (EASO) recommends semaglutide and tirzepatide as primary pharmacotherapies for obesity and related complications.
Tirzepatide can yield 20% weight loss over 72 weeks.
Framework prioritizes patient-centered care, considering health conditions and socioeconomic factors.
High costs restrict accessibility, notably in Spain.
Guidelines should update as evidence emerges; experts urge combining medication with lifestyle changes.